Analyst David Risinger from Leerink Partners reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report) and increased the price ...

Canaccord Genuity adjusted its outlook on Akero Therapeutics (NASDAQ: NASDAQ:AKRO) shares, raising the price target to $73 ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human pancreatic tumors harboring a G12D mutation ...

Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company has ...

Immunotherapy, cancer treatments that alter the immune system, making it better apt to fight tumor cells, have provided novel ...

(Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors ... ALX40-4C NPS Allelix Terminated (Phase I/II) HIV No apparent effect was observed on ...

Major depressive disorder (MDD) is a leading cause of disability worldwide and unfortunately no treatment without side effects is available. Previous reports have found unbalanced glutamate-glutamine ...

The tissue adjacent to a tumor behaves differently than areas farther away: The tumor's cancerous cells influence their ...